Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage

Journal of Molecular Neuroscience

Volumn 31, Issue 2, 2007, Pages 165-170

  Matsuoka, Yasuji ^a   Gray, Audrey J ^a   Hirata Fukae, Chiho ^a   Minami, S Sakura ^a   Waterhouse, Emily Graeme ^a   Mattson, Mark P ^b   LaFerla, Frank M ^c   Gozes, Illana ^d   Aisen, Paul S ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Intranasal administration; NAP; Neuroprotection; Phosphorylation; Tau; Therapy; Transgenic mouse; amyloid peptide

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ASPARAGINYLALANYLPROLYLVALYLSERYLISOLEUCYLPROLYLGLUTAMIC ACID; OCTAPEPTIDE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; MICROTUBULE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

EID: 34248354279     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Aisen P. S. (2005) Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. J. Am. Acad. Nurse Pract. Suppl. 5-7.
2. Ashur-Fabian O., Segal-Ruder Y., Skutelsky E., Brenneman D. E., Steingart R. A., Giladi E., and Gozes I. (2003) The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides 24, 1413-1423.
3. Avila J., Lucas J. J., Perez M., and Hernandez F. (2004) Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84, 361-384.
4. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72, 1283-1293.
5. Bhat R. V., Budd Haeberlein S. L., and Avila J. (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89, 1313-1317.
6. Brenneman D. E. and Gozes I. (1996) Afemtomolar-acting neuroprotective peptide. J. Clin. Invest. 97, 2299-2307.
7. Cho J. H. and Johnson G. V. (2003) Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J. Biol. Chem. 278, 187-193.
8. Divinski I., Holtser-Cochav M., Vulih-Schultzman I., Steingart R. A., and Gozes I. (2006) Peptide neuroprotection through specific interaction with brain tubulin. J. Neurochem. 98, 973-984.
9. Divinski I., Mittelman L., and Gozes I. (2004) A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J. Biol. Chem. 279, 28,531-28,538.
10. Frame S., Cohen P., and Biondi R. M. (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321-1327.
11. Furman S., Steingart R. A., Mandel S., Hauser J. M., Brenneman D. E., and Gozes I. (2004) Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol. 1, 193-199.
12. Gervais F., Paquette J., Morissette C., Krzywkowski P., Yu M., Azzi M., et al. (2006) Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging, in press.
13. Gozes I. (2001) Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci. 24, 700-705.
14. Gozes I. and Divinski I. (2004) The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection. J. Alzheimer Dis. 6, S37-S41.
15. Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D. E., and Spier A. D. (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Mol. Neurosci. 20, 315-322.
16. Gozes I., Giladi E., Pinhasov A., Bardea A., and Brenneman D. E. (2000) Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improves performance in a water maze. J. Pharmacol. Exp. Ther. 293, 1091-1098.
17. Gozes I., Morimoto B. H., Tiong J., Fox A., Sutherland K., Dangoor D., et al. (2005) NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 11, 353-368.
18. Greenberg S. G. and Davies P. (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. U. S. A. 87, 5827-5831.
19. Guo Q., Fu W., Sopher B. L., Miller M. W., Ware C. B., Martin G. M., and Mattson M. P. (1999) Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat. Med. 5, 101-106.
20. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
21. Horikoshi Y., Sakaguchi G., Becker A. G., Gray A. J., Duff K., Aisen P. S., et al. (2004) Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem. Biophys. Res. Commun. 319, 733-737.
22. Jankowsky J. L., Xu G., Fromholt D., Gonzales V., and Borchelt D. R. (2003) Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62, 1220-1227.
23. Kosik K. S., Orecchio L. D., Binder L., Trojanowski J. Q., Lee V. M., and Lee G. (1988) Epitopes that span the tau molecule are shared with paired helical filaments. Neuron 1, 817-825.
24. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., et al. (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23, 29-33.
25. Mercken M., Vandermeeren M., Lubke U., Six J., Boons J., Van de Voorde A., et al. (1992) Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 84, 265-272.
26. Oddo S., Caccamo A., Kitazawa M., Tseng B. P., and LaFerla F. M. (2003a) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24, 1063-1070.
27. Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., et al. (2003b) Triple-transgenic model of Alzheimer's disease with plaques and tangles. Intracellular abeta and synaptic dysfunction. Neuron 39, 409-421.
28. Oddo S., Caccamo A., Smith I. F., Green K. N., and LaFerla F. M. (2006) A dynamic relationship between Intracellular and extracellular pools of Abeta. Am. J. Pathol.168,184-194.
29. Pinhasov A., Mandel S., Torchinsky A., Giladi E., Pittel Z., Goldsweig A. M., et al. (2003) Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res. Dev. Brain Res. 144, 83-90.
30. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H. J. (2003) Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333-1341.
31. Said S. I. (1996) Molecules that protect: the defense of neurons and other cells. J. Clin. Invest 97, 2163-2164.
32. Wagner U., Utton M., Gallo J. M., and Miller C. C. (1996) Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J. Cell Sci. 109(Pt. 6), 1537-1543.
33. Weingarten M. D., Lockwood A. H., Hwo S. Y., and Kirschner M. W. (1975) A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U. S. A. 72, 1858-1862.
34. Zemlyak I., Furman S., Brenneman D. E., and Gozes I. (2000) A novel peptide prevents death in enriched neuronal cultures. Regul. Pept. 96, 39-43.